Östersund Hospital
Östersund, Alberta, 83183, Sweden
NCT Number: NCT02733406
Hypotension will often complicate induction of anaesthesia. The investigators want to test the hypothesis that Target Controlled Infusion, as opposed to Velocity Controlled Infusion, leads to less degree of hypotension.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Östersund, Alberta, 83183, Sweden
Severe hypotension may be a serious complication to induction of anaesthesia. The patients preoperative clinical circulatory status will help define the risks of such a side-effect. A patient with a preexisting heart condition will be at increased risk for morbidity/mortality in relation to anaesthesia induction.
Total intravenous anaesthesia may be delivered by two different approaches. The old way where the drug (Propofol and/or Remifentanil) is delivered in a velocity (mg/kg x hour or microg/ kg x min) specified by the anaesthetist. Hereafter called Velocity Controlled Infusion (VCI). At induction, to get effect of the drug, a high infusion rate is desired. A high infusion rate is associated with increased risks of hypotension if it is not adjusted in accordance with the current circulatory status of the patient. A failure to adjust may be futile for the patient. Therefore, induction takes some time because infusion rate is set within a relatively safe range. After a few minutes, once airway control is achieved, the infusion rate must be adjusted down to avoid hypotension.
There is a more modern way of adjusting the infusion rate, the so called Target Controlled Infusion. With this approach, the pump delivering the drug will help the anaesthetist to select the appropriate infusion rate for any given situation. The anaesthetist selects a preferred concentration of the drug at the target, that is in the circulation. The pump then administrates the drug, first at high rate and then at lower rate, taking into account the patients age, weight and sex and the preferred target concentration.
It is possible that this help from the machine is associated with less risk for hypotension at anaesthesia induction. If this is so it would have an impact on which of TCI and VCI that would be the best choice of anaesthesia. This would have special impact when giving anaesthesia to patients with a heart condition.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 20 minutes
Relative maximal decrease of blood pressure (in mmHg) by anaesthesia induction (%)
Time frame: 20 minutes
Number of doses of drug to increase blood pressure
Time frame: From the start of anaesthesia induction to the time of airway control (Laryngeal airway working in place of tracheal tube working in place).
Amount (milligram) of Propofol delivered and amount (mikrogram) of Remifentanil delivered.
Time frame: From end of anaesthesia to 2 hours or when leaving the PostAnaesthesia Care Unit
Dose and name of any drug given to reduce PONV at any time defined above (in addition to profylaxis with the same aim)
Umeå University
Other
The Effect of Target Controlled Infusion as Opposed to Velocity Controlled Infusion on Hypotension at Induction of Total Intravenous Anaesthesia
Acronym: HEAT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02919917
Autonomic Dysreflexia, Autonomic Nervous System Diseases
New York, United States
View Trial DetailsNCT05685212
Anesthesia, Spinal, Blood Pressure
La Marsa, Tunis Governorate, Tunisia
View Trial DetailsNCT05725148
Blood Pressure, Cardiovascular Diseases
Gyeonggi-do, Pangyo, South Korea
View Trial DetailsNCT04082819
Blood Pressure, Cardiovascular Diseases
Markham, Ontario, Canada
View Trial Details